Drugs / suvodirsen
suvodirsen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03508947 | Jan 2018 → Mar 2019 | Duchenne muscular dystrophy | Wave Life Sciences USA, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03907072 | Sep → Dec 2019 | Duchenne muscular dystrophy | Wave Life Sciences USA, Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | suvodirsen | “WVE-210201 (suvodirsen)” NCT03907072 ↗ |
| Known as | BMTR0139 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298192 ↗ |
| Known as | WLS-4176 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298192 ↗ |
| Known as | WV-3473 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298192 ↗ |
| Known as | WVE-210201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03508947 ↗ |
| Modality | Antisense oligonucleotide | “WVE-210201 is a stereopure antisense oligonucleotide (ASO)” NCT03508947 ↗ |
| Route | Intravenous | “WVE-210201 Administered Intravenously” NCT03508947 ↗ |